Skip to content

An exploratory study for CTC periodic monitoring for maintenane therapy of SCLC

An exploratory study for CTC periodic monitoring for maintenane therapy of SCLC

Status
Active, not recruiting
Phases
Unknown
Study type
Observational
Source
ChiCTR
Registry ID
ChiCTR1800019272
Enrollment
Unknown
Registered
2018-11-02
Start date
2018-12-31
Completion date
Unknown
Last updated
2018-11-05

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

small cell lung cancer

Interventions

Case series:VP-16 metronomic chemotherapy

Sponsors

Baoji Central Affiliated Hospital of Xi'an Jiaotong University
Lead Sponsor

Eligibility

Sex/Gender
All
Age
18 Years to 75 Years

Inclusion criteria

Inclusion criteria: 1. Pathological diagnosis of newly diagnosed adult small cell lung cancer, including those early stage SCLC who received radical operation and adjuvant treatment relapsed for the first time after operation; 2. Patient who adapted for chemotherapy by EP regimen according to 2018 NCCN V2; 3. Aged 18-75 years old male and female; 4. ECOG score 0-2; 5. Having at least one evaluable lesion (refer to RECIST 1.1),including CT or MRI; 6. No functional disturbance of main organ and function levels meet the following criteria; (1) Blood routine examination criteria should be consistent with: ANC=1.5×10^9/L, PLT=80×10^9/L, Hb=90g/L; (2) Biochemical examination should meet the following criteria: TBIL<2×ULN, ALT, AST<2.5×ULN; (3) Renal function of serum creatinine =140mol/L; 7. Subjects voluntarily participated in this study, signed informed consent; 8. Anticipated lifetime=3 months.

Exclusion criteria

Exclusion criteria: 1. Patients with other malignant tumors (except for completely cured cervical carcinoma in situ or basal cells or squamous epithelial skin cancer); 2. Patients who received anti-tumor treatment before; 3. Patients with congestive cardiac failure, unstable angina, myocardial infarction, hypertension and antihypertensive medication can not be reduced to normal range, un-controlling arrhythmia or other history of heart diseases; LVEF<55%; 4. Pregnant, lactating women or those who have fertility are unwilling or unable to take effective contraceptive measures; 5. Blood sample become to coagulation or hemolysis; 6. The investigator believes that it is not suitable for inclusion.

Design outcomes

Primary

MeasureTime frame
cirvulating tumor cells;

Countries

China

Contacts

Public ContactZhao Ya'ning

Baoji Central Affiliated Hospital of Xi'an Jiaotong University

zyn13649179265@163.com+86 13649179265

Outcome results

None listed

Source: ChiCTR (via WHO ICTRP) · Data processed: Feb 4, 2026